Mechanistically, they selectively target pathways dysregulated in breast cancer, such as PI3K/AKT/mTOR and STAT3, while sparing normal cells, a critical advantage over conventional chemotherapies [27,28]. This evidence concerns the gene MTOR and breast cancer.